In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA revises iPLEDGE dates

Executive Summary

FDA revises implementation dates for iPLEDGE, the risk management program for Roche's Accutane and isotretinoin generics, to allow more time for registration and activation, agency announces Oct. 28. Wholesalers and pharmacies must now be registered/activated on iPLEDGE by Dec. 30, rather than Nov. 1. The patient registration start date also has been pushed back from Nov. 1 to Dec. 30. After March 1, only prescribers activated in iPLEDGE are permitted to prescribe isotretinoin to patients who are registered in the risk management program. FDA adopted the program in August as part of a restricted distribution initiative aimed at preventing pregnancies in patients taking the acne medication (1"The Pink Sheet" Aug. 22, 2005, p. 12)...

You may also be interested in...

Accutane Update Is First Time For Wholesaler Instructions In A Product Label

A recently approved risk management program to prevent pregnancies in patients taking isotretinoin (Roche's Accutane and generics) includes the unprecedented addition of wholesaler-focused instructions to prescription drug labeling

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts